OCKET NO : RTS=0350 "Express Mail" Label No : EV053176273US

DOCKET NO.:RTS-0350 "Express Mail" Label No.: EV053176273US
Date of Deposit: 12 06 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Susan M. Freier et al.

Serial No.: Not yet assigned Group No.: Not yet assigned

Filed: herewith

For: Antisense Modulation of PCTAIRE protein kinase 1 Expression

BOX SEQUENCE Assistant Commissioner for Patents Washington DC 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. \$1.56 and in accordance with 37 C.F.R. \$\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. \$1.56(b).

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above identified application, no additional fee is required.

Copies of each of the references listed on the attached Form PTO-1449 are enclosed.

Date: Darember 6, 200

Respectfully submitted,

Downna T. Ward

Registration No. 48,271

ISIS PHARMACEUTICALS, INC. Carlsbad Research Center 2292 Faraday Avenue Carlsbad, CA 92008

"Express Mail" Label No.: EV053176273US Date of Deposit: 12/06/2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Susan M. Freier and Mark P. Roach

For: Antisense Modulation of PCTAIRE protein kinase 1 Expression

BOX SEQUENCE Assistant Commissioner for Patents Washington DC 20231

PATENT APPLICATION TRANSMITTAL LETTER

Transmitted herewith for filing, please find the following:

- · The specification of the above-referenced patent application;
- · An executed Declaration or Oath and Power of Attorney;
- An Assignment of the invention to Isis Pharmaceuticals Inc. with recordation cover sheet (PTO Form PTO-1595) and \$40.00 cover fee;
- Statement to Support Filing and Submission of DNA/Amino Acid Sequences in Accordance with 37 CFR § § 1.821 through 1.825;
- Sequence listing in computer readable form in accordance with 37 C.F.R. § 1.821(e);
- · An Information Disclosure Statement with references; and
- Applicant claims small entity status pursuant to 37 CFR § 1.27.

The filing fee has been calculated as shown below:

No. Filed	No. Extra	Rate	Fee
BASE FEE			\$370.00
20 - 20 =	0	X \$9=	\$0
2 - 3 =	0	x\$40=	\$0
	20 - 20 =	20 - 20 = 0	20 - 20 = 0 x \$9=

The Commissioner is hereby authorized to charge the following fees to Deposit Account No. 500252:

- the amount of \$410.00 for the above listed fees;
- payment of the following fees associated with this communication or credit any overpayment;
- any additional filing fees required under 37 CFR 1.16 including fees for presentation of extra claims; and
- $^{\circ}$ any additional patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20 (d).

Triplicate copies of this transmittal are enclosed.

Date: December 6, 2001

(856) 810-1515

Donna T. Ward

Registration No. 48,271
Isis Pharmaceuticals, Inc.

Please address all correspondence to: Jane Massey Licata or Kathleen A. Tyrrell Licata & Tyrrell, P.C. 66 East Main Street Marlton NJ 08053

#3/I.D.S.

DOCKET NO.:RTS-0350

"Express Mail" Label No.: EV053176273US Date of Deposit: 1200 200

Form PTO-1449 Modified			Docket No.	Serial No.		
			RTS-0350	not yet assigned		
List of Patents and Publications			Applicant			
Cited by Application			Susan M. Freier et al.			
(Use several sheets if necessary)			basan m. ricici ee a	î		
(obe beveral bliceob if liceobally)		Filing Date	Group (1)			
U.S. Department of Commerce Patent and			herewith			
Trademark Office			Herewich			
TIAGCMAIN OF			II.	40		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	AA	Hirose et al., Ide	Identification of tudor repeat			
		associator with PCTAIRE 2 (Trap). A novel protein that				
		interacts with the N-terminal domain of PCTAIRE 2 in rat brain, Eur. J. Biochem., 2000, 267:2113-2121				
	ΑB	Meyerson et al., A family of human cdc2-related				
		protein kinases, Th	he Embo Journal, 1992 , 11:2909-2917			
	AC	Morgan, Principles	inciples of CDK regulation, Nature, 1995,			
		374:131-134				
	AD	Okuda et al., PCTAIRE-1 and PCTAIRE-3, two members of				
		a novel cdc2/CDC28-related protein kinase gene family,				
		Oncogene, 1992 , 7:2249-2258				
	AE	Okuda et al., Cloning of genomic loci and chromosomal				
		localization of the human PCTAIRE-1 and -3 protein				
		kinase genes, Genomics, 1994 , 21:217-221				
	AF	Sladeczek et al., The Cdk-like protein PCTAIRE-1 from				
		mouse brain associates with pll and 14-3-3 proteins,				
Mol. Gen. Genet., 1997 , 254:571-577						
EXAMINER			DATE CONSIDERED			